title: Prostaglandin E1 infusion for right ventricular failure after cardiac transplantation.
abstract: The infusion of prostaglandin E1, a vasodilating substance with predominant effects on the pulmonary vasculature, has been found effective in the management of pulmonary hypertension associated with various diseases. The reported experience with prostaglandin E1 after cardiac transplantation is, however, limited. We used prostaglandin E1 in 18 patients in whom acute right ventricular failure developed after orthotopic cardiac transplantation. The infusion was started within 24 hours after operation in 16 patients and was continued for up to 7 days. Maximal doses of prostaglandin E1, administered via a central venous catheter, ranged from 30 to 120 ng/kg/min. Norepinephrine was simultaneously infused via a left atrial catheter in 10 patients to prevent a reduction in systemic arterial pressure. The prostaglandin E1 infusion resulted in significant reductions in mean arterial pressure and pulmonary vascular resistance and simultaneous increases in cardiac index and stroke index. Mean arterial pressure was stable and left ventricular stroke work increased. The alveolar oxygen tension/forced inspiratory oxygen index tended to decrease during the infusion. Three patients died, two of right heart failure and one of multiple organ failure associated with cardiac allograft rejection. In patients in whom right ventricular failure associated with pulmonary hypertension develops after cardiac transplantation, prostaglandin E1, combined with norepinephrine whenever the arterial pressure declines, can effectively reduce pulmonary artery pressures and improve global cardiac function without compromising systemic perfusion.
authors.affiliation: Department of Intensive Care, Erasme University Hospital, Free University of Brussels, Belgium.
authors.forename: J L
authors.initials: JL
authors.lastname: Vincent
authors.forename: E
authors.initials: E
authors.lastname: Carlier
authors.forename: M R
authors.initials: MR
authors.lastname: Pinsky
authors.forename: J
authors.initials: J
authors.lastname: Goldstein
authors.forename: R
authors.initials: R
authors.lastname: Naeije
authors.forename: P
authors.initials: P
authors.lastname: Lejeune
authors.forename: S
authors.initials: S
authors.lastname: Brimioulle
authors.forename: J L
authors.initials: JL
authors.lastname: Leclerc
authors.forename: R J
authors.initials: RJ
authors.lastname: Kahn
authors.forename: G
authors.initials: G
authors.lastname: Primo
mesh_terms: D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use*; D006328:Cardiac Catheterization; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000209:etiology; D002405:Catheterization, Central Venous; D016027:Heart Transplantation; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000008:administration & dosage / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy*; D016278:Ventricular Function, Right / Q000187:drug effects*
chemical_list: D000527:Alprostadil; D009638:Norepinephrine